Pharmaceuticals company Jagsonpal Pharmaceuticals announced Q3FY25 results Revenue: Rs 740 milllion compared to Rs 472 million during Q3FY24, change 57%. Operating EBITDA: Rs 171 million compared to Rs 60 million during Q3FY24. EBITDA Margin: 23.1% for Q3FY25. ESOP cost: Rs 13 million compared to Rs 27 million during Q3FY24, change -52%. Manish Gupta, Managing Director and CEO, Jagsonpal Pharmaceuticals said: “I am pleased with the Q3FY25 performance that is reflective of the strategic choices we have made. With revenues of Rs 740 million, a 57% growth YoY, and a 183% YoY increase in operating EBITDA (pre-ESOP) to Rs 171 million, our performance demonstrates an effective alignment of our operations with market opportunities. The sale of Faridabad facility for Rs 410 million has further strengthened our financial foundation. The cash position of Rs 1,321 million as of December 31, 2024, gives us the flexibility to invest in areas that promise sustainable growth. On a YTD basis, our 27% revenue growth to Rs 2102 million, coupled with a 53% rise in operating EBITDA to Rs 482 million with 390 bps margin expansion, highlights the success of our business discipline and seamless integration of acquired business. As we move forward, we shall continue to remain focused on organic growth supported by strategic inorganic initiatives leveraging our internal accruals to build a more resilient and dynamic organisation.” Result PDF